Endocannabinoid Pharmacology Meeting - 2015
29–30 October 2015
The main objective of the Endocannabinoid Pharmacology Meeting is to provide a summary of the state-of-art of the pharmacology and therapeutic exploitation of the endocannabinoid system (ECS), focusing on the current and future directions undertaken by the scientific community and pharmaceutical companies, with the aim of bridging basic research and the potential translational aspects.
Another objective is to gather scientists and students working at different levels on the ECS in academia and industry, creating an interactive and inspiring atmosphere for exchanging scientific knowledge and insights.
In the last twenty years, many efforts have been carried out to elucidate the best pharmacological ways of modulating this system. This has led to the identification and characterization of several new classes of bioactive small molecules.
Unfortunately, despite promising pre-clinical results none of these compounds have successfully completed the clinical development, apart for the cannabinoid receptor 1 (CB1) antagonist/inverse agonist rimonabant (Acomplia) which was approved as anti-obesity drug in 2006, but further withdrawn from the market 2 years later. Therefore, the translation of pre-clinical drug candidates into effective therapeutic agents still remains an open challenge in the ECS.